KSC Equity Snapshot
326030 Weekly Equity Report
SK Biopharmaceuticals Co., Ltd.
What the company does
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment …
What the weekly tape is saying
326030 closed the latest completed week at 87,900 KRW. The 4-week return is -9.0% and the 12-week return is -10.9%. Trend Signal is inactive, Market Dynamics is -0.63. Setup signature: Risk-first tape with a 19/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 110,100 KRW
- Vs Trend Line
- -20.2%
- Fair Value
- 99,015 KRW
- Vs Fair Value
- -11.2%
- 52W High
- 144,100 KRW
- 52W Low
- 81,000 KRW
- Drawdown
- -39.0%
- Range Position
- 10.9%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 20
- 52W Active Breadth
- 38.5%
- Sector Scope
- KR Healthcare
- Sector Rank
- 30 of 63
- Sector Percentile
- 53.2%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
KR Healthcare
- Tracked Peers
- 63
- 4W Rank
- 17 of 63
- Avg 1W
- -1.0%
- Avg 4W
- -12.7%
- Trend Breadth
- 1.6%
- Positive MD
- 6.3%
KR Biotechnology
- Tracked Peers
- 10
- 4W Rank
- 5 of 10
- Avg 1W
- -0.9%
- Avg 4W
- -11.2%
- Trend Breadth
- 0.0%
- Positive RS
- 0.0%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.63
- 4W MD Change
- 14.0%
- Relative Strength
- -56.62
- 4W RS Change
- -9.7%
- Expectation
- Undecided
- Probability
- 53.14%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 1.8M
- 13W Average
- 2.3M
- 52W Average
- 1.4M
- Vs 13W
- 0.8x
- Vs 52W
- 1.2x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 4.0%
- 52W Volatility
- 5.0%
- Upside Weeks
- 23
- Downside Weeks
- 28
- Downside Breadth
- 53.8%
- Avg Gain / Loss
- 4.4% / -3.5%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- KSC
- Country
- KR
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- KRW
- Market Cap
- 6977.7B
Opportunity signals
- No strong opportunity cluster is confirmed yet; monitor trend and Market Dynamics.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 87,900 KRW | -0.2% | 110,100 KRW | 99,015 KRW | -0.63 | -56.62 | 1.8M | Off |
| 5 Jun 2026 | 88,100 KRW | -1.8% | 111,447 KRW | 99,001 KRW | -0.59 | -57.39 | 1.2M | Off |
| 29 May 2026 | 89,700 KRW | -8.3% | 112,377 KRW | 98,910 KRW | -0.54 | -58.90 | 5.6M | Off |
| 22 May 2026 | 97,800 KRW | 1.2% | 113,237 KRW | 98,818 KRW | -0.63 | -52.45 | 1.2M | Off |
| 15 May 2026 | 96,600 KRW | -2.8% | 113,527 KRW | 98,654 KRW | -0.73 | -51.60 | 1.6M | Off |
| 8 May 2026 | 99,400 KRW | -0.5% | 113,673 KRW | 98,491 KRW | -0.76 | -50.99 | 905.1K | Off |
| 1 May 2026 | 99,900 KRW | -2.3% | 113,823 KRW | 98,315 KRW | -0.89 | -44.89 | 592.4K | Off |
| 24 Apr 2026 | 102,300 KRW | -3.0% | 113,977 KRW | 98,142 KRW | -1.03 | -43.55 | 808.7K | Off |
| 17 Apr 2026 | 105,500 KRW | 7.1% | 113,950 KRW | 97,928 KRW | -1.03 | -40.13 | 953.4K | Off |
| 10 Apr 2026 | 98,500 KRW | 4.7% | 114,013 KRW | 97,696 KRW | -1.19 | -41.91 | 710.5K | Off |
| 3 Apr 2026 | 94,100 KRW | -6.2% | 114,430 KRW | 97,552 KRW | -1.19 | -40.53 | 1.1M | Off |
| 27 Mar 2026 | 100,300 KRW | 1.7% | 114,933 KRW | 97,350 KRW | -1.10 | -38.30 | 12.2M | Off |
| 20 Mar 2026 | 98,600 KRW | 0.8% | 114,877 KRW | 97,113 KRW | -1.01 | -43.70 | 829.5K | Off |
| 13 Mar 2026 | 97,800 KRW | -5.0% | 114,887 KRW | 96,872 KRW | -0.97 | -41.99 | 1.0M | Off |